In a new paper published in the journal Alzheimer’s Research & Therapy, the AMYPAD consortium investigated main enrollment barriers in individuals with no or mild symptoms recruited from research and clinical parent cohorts (PCs) of ongoing observational studies for the large European longitudinal biomarker study, namely thhe AMYPAD Prognostic and Natural History Study (PNHS).

The enrollment rate for the AMYPAD -PNHS was relatively high, suggesting an advantage of recruitment via ongoing studies. In this observational cohort, study burden reduction and tailored strategies may potentially improve participant enrollment into trial readiness cohorts such as for phase-3 early anti-amyloid intervention trials.

Congratulations to all authors: Ilse Bader, Ilona Bader, Isadora Lopes Alves, David Vállez García, Bruno Vellas, Bruno Dubois, Mercè Boada, Marta Marquié, Daniele Altomare, Philip Scheltens, Rik Vandenberghe, Bernard Hanseeuw, Michael Schöll, Giovanni B. Frisoni, Frank Jessen, Agneta Nordberg, Miia Kivipelto, Craig W. Ritchie, Oriol Grau-Rivera, José Luis Molinuevo, Lisa Ford, Andrew Stephens, Rossella Gismondi andJuan Domingo Gispert.

You can read the paper here: https://doi.org/10.1186/s13195-023-01332-4